Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
Revance Therapeutics, Inc. (RVNC)
Last revance therapeutics, inc. earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.revance.com
Company Research
Source: Business Wire
- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%.- DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program.- Toxin market share increased from 3.0% in Q4’23 to 3.7% in Q1’24.- Aesthetic units sold increased 105% YoY and 7% QoQ, despite traditional seasonality.- RHA® Collection net revenue of $29.6 million; filler market share increased from 9.1% in Q4’23 to 9.8% in Q1’24.- Revance launches DAXXIFY for Cervical Dystonia, with coverage for 78% of commercial lives and continued positive real-world physician feedback from PrevU program.- Revance continues to expect 2024 total net product revenue, which includes sales of DAXXIFY and the RHA Collection, to be at least $280 million.- Conference call and webcast today at 4:30 p.m. ET. NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the first quarter ended March 31, 2024 a
Show less
Read more
Impact Snapshot
Event Time:
RVNC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVNC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVNC alerts
High impacting Revance Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RVNC
News
- Revance Therapeutics, Inc. (NASDAQ: RVNC) had its price target lowered by analysts at HC Wainwright from $12.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Revance Therapeutics, Inc. (NASDAQ: RVNC) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $9.00 to $8.00. They now have a "neutral" rating on the stock.MarketBeat
- Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Revance Therapeutics, Inc. (NASDAQ: RVNC) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $11.00 price target on the stock, down previously from $20.00.MarketBeat
- Revance Therapeutics, Inc. (NASDAQ: RVNC) had its price target lowered by analysts at Needham & Company LLC from $18.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
RVNC
Earnings
- 5/9/24 - Beat
RVNC
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 5/3/24 - Form 8-K
- RVNC's page on the SEC website